Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 12/20 | 0.51 |
| ▸ | HRH1 | P35367 | 3/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6332815 | 1.00 | SSTR5 (0.51) | SSTR5HRH1HTR2BSIGMAR1OPRK1 | |
| SCHEMBL6332820 | 1.00 | SSTR5 (0.51) | SSTR5HRH1HTR2BSIGMAR1OPRK1 | |
| SCHEMBL6322893 | 0.89 | CCR3 (0.43) | SSTR5HRH1HTR2BSIGMAR1 | |
| SCHEMBL6327582 | 0.87 | CCR3 (0.52) | SSTR5HRH1HTR2BOPRK1 | |
| SCHEMBL6327593 | 0.87 | CCR3 (0.52) | SSTR5HRH1HTR2BOPRK1 | |
| SCHEMBL6327587 | 0.87 | CCR3 (0.52) | SSTR5HRH1HTR2BOPRK1 | |
| SCHEMBL6325112 | 0.86 | DRD2 (0.44) | SSTR5HRH1HTR2B | |
| SCHEMBL5783867 | 0.79 | SSTR5 (0.49) | SSTR5HRH1HTR2BSIGMAR1OPRK1 | |
| SCHEMBL6326359 | 0.79 | SSTR5 (0.52) | SSTR5HRH1HTR2BSIGMAR1OPRK1 | |
| SCHEMBL6325942 | 0.79 | SIGMAR1 (0.46) | HTR2BSIGMAR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090504-A1 | Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists | ROCHE PALO ALTO LLC | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090504-A1 | Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists | CCR9, CCR3, CCR1 | SSTR5 908/4885HRH1 250/4885HTR2B 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.